SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Repros Therapeutics Inc.'s New IND for the Investigation of Androxal(R) in the Treatment of Type II Diabetes in Men with Secondary Hypogonadism is Now Effective